Driver and Passenger Alterations

Driver and Passenger Alterations is a classification framework used in cancer genomics to distinguish genetic changes that actively contribute to tumor development and progression from those that arise incidentally during the course of tumor evolution without conferring any selective growth advantage. This distinction is central to interpreting the thousands of mutations, copy number changes, and structural variants typically found within a cancer genome.

Driver Alterations

Definition and Selective Advantage

Driver alterations are mutations or structural changes that confer a fitness advantage to the cell in which they occur, promoting hallmark cancer behaviors such as sustained proliferation, evasion of growth suppressors, resistance to cell death, replicative immortality, angiogenesis, and invasive or metastatic capacity. Because they are positively selected for during clonal evolution, driver alterations tend to recur across many independent tumors and patients.

Types of Driver Genes

Driver alterations typically affect two broad categories of genes. Oncogenes become activated through gain-of-function mutations, amplification, or translocation, driving excessive proliferative signaling. Tumor suppressor genes become inactivated through loss-of-function mutations, deletions, or epigenetic silencing, removing the normal restraints on cell growth and genome stability.

Recognizing Drivers

Bioinformatic and statistical approaches identify likely driver alterations by looking for mutations that recur at significantly higher frequency than expected by chance, that cluster at functionally important protein domains, or that show patterns of positive selection across large cohorts of sequenced tumors.

Passenger Alterations

Definition and Neutral Origin

Passenger alterations are mutations that accumulate in the genome as a byproduct of the elevated mutation rates, replication errors, and genomic instability characteristic of cancer cells, but that do not themselves provide any growth or survival benefit. They are carried along, or "pass along," within the same clonal population as the true driver alterations.

Abundance

The overwhelming majority of somatic alterations detected in a typical tumor genome are passengers rather than drivers. A single tumor may harbor only a handful of true driver alterations alongside tens to thousands of passenger mutations, depending on tumor type and mutational burden.

Sources of Passenger Mutations

Passenger alterations arise from ongoing replication errors, exposure to mutagens such as ultraviolet light or tobacco carcinogens, defective DNA repair pathways, and the general genomic instability that accompanies malignant transformation.

Distinguishing Drivers from Passengers

Statistical Recurrence

One of the primary strategies for identifying drivers is to search for genes or specific mutation hotspots that appear far more often across a cohort of tumors than would be expected from the background mutation rate alone.

Functional Impact Prediction

Computational tools estimate whether a given mutation is likely to disrupt protein structure or function, favoring alterations that affect conserved residues, active sites, or domains known to be important for the protein's biological role.

Experimental Validation

Functional assays in cell culture and animal models can directly test whether introducing a candidate alteration confers a growth advantage, providing definitive evidence of driver status beyond statistical inference alone.

Context Dependence

An alteration may act as a driver in one tissue type or genetic background and behave as a passenger in another, meaning that driver status is not always an absolute property of the mutation itself but can depend on the cellular context in which it occurs.

Clinical Relevance

Therapeutic Targeting

Identifying true driver alterations is essential for precision oncology, since therapies designed to inhibit an oncogenic driver are only effective in tumors that actually depend on that alteration for their growth. Passenger alterations, in contrast, are not meaningful therapeutic targets.

Tumor Evolution and Heterogeneity

Distinguishing drivers from passengers also informs the study of clonal evolution within a tumor, helping researchers reconstruct which alterations were present in the founding clone versus which arose later as neutral or subclonal passengers during tumor progression and metastasis.